Atovaquone 750 mg in 5 mL Oral Suspension
RxNorm 308429
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 308429 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: atovaquone 750 mg in 5 mL Oral Suspension.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Atovaquone 150 mg/ML Oral Suspension
(Atom ID: 12329382)
PTPrescribable
Designated preferred name (PT):
Atovaquone 150 mg/mL oral suspension
(Atom ID: 10294483)
SYPrescribable
Synonym (SY):
Atovaquone 1500 mg per 10 mL Oral Suspension
(Atom ID: 12717028)
PSNPrescribable
Prescribable Name (PSN):
Atovaquone 750 mg in 5 mL Oral Suspension
(Atom ID: 8725159)
SYPrescribable
Synonym (SY):
Atovaquone 750 mg per 5 mL Oral Suspension
(Atom ID: 3309191)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely atovaquone 150 mg/1 mL conventional release oral suspension (clinical drug)
(Atom ID: 10309535)
Patient Education
Atovaquone
Atovaquone is used to treat Pneumocystis jiroveci [Pneumocystis carinii] pneumonia (PCP; type of pneumonia most likely to affect people with human immunodeficiency virus [HIV]) in teenagers and adults. Atovaquone is also used to prevent PCP in teenagers and adults who cannot take another medication used for prevention. Atovaquone is in a class of medications called antiprotozoal agents. It works by stopping the growth of certain types of protozoa that can cause pneumonia.
[Learn More]
* Please review the disclaimer below.